Abstract
This article describes a dataset for a meta-analysis that aimed to investigate the effects of treatment on the neurometabolite status in patients with schizophrenia (DOI of original article: https://doi.org/10.1016/j.schres.2020.03.069[1]). The data search was performed with MEDLINE, Embase, and PsycINFO. The neurometabolites investigated include glutamate, glutamine, glutamate + glutamine, gamma-aminobutyric acid, N-acetylaspartate, and myo-inositol, and the regions of interest (ROIs) include the frontal cortex, temporal cortex, parieto-occipital cortex, thalamus, basal ganglia, and hippocampus. The meta-analysis was conducted with a random-effects model, and the use of the standardized mean difference method between pre- and post-treatment of subjects for neurometabolites in each ROI of three patient groups or more. The dataset covers raw data of 39 patient groups (773 patients with schizophrenia at follow-up) with neurometabolite levels measured by magnetic resonance spectroscopy both before and after treatment. Furthermore, it contains details of clinical characteristics and treatment types for each group. Therefore, the data would be useful for a reinvestigation of treatment effects on the neurometabolite status from diverse points of view, as well as for the development of future treatment strategies for psychiatric diseases.
Highlights
This article describes a dataset for a meta-analysis that aimed to investigate the effects of treatment on the neurometabolite status in patients with schizophrenia
The dataset covers raw data of 39 patient groups (773 patients with schizophrenia at followup) with neurometabolite levels measured by magnetic resonance spectroscopy both before and after treatment
The dataset covers 39 patient groups (773 patients with schizophrenia at follow-up) with neurometabolite data for both before and after treatment, which allows for a reinvestigation of the treatment effects on the neurometabolite status from diverse points of view
Summary
Meta-analysis of proton magnetic resonance spectroscopy (1 H-MRS) data of treatment effects on neurometabolite levels in schizophrenia [1]. We used the following search terms: (MRS OR "magnetic resonance spectroscopy") AND (schizophrenia OR schizoaffective OR psychosis OR "high risk" OR UHR OR ARMS OR prodrom∗ ). From longitudinal and randomized control research, we collected MRS data of both before and after treatment in patients with schizophrenia. Treatment effects on neurometabolite levels in schizophrenia: A systematic review and meta-analysis of proton magnetic resonance spectroscopy studies, Schizophr. The dataset covers 39 patient groups (773 patients with schizophrenia at follow-up) with neurometabolite data for both before and after treatment, which allows for a reinvestigation of the treatment effects on the neurometabolite status from diverse points of view. The dataset would be useful for conducting a future meta-analysis associated with treatment intervention in various diseases
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
